Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

119.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,356
Open 119.23
Bid (Size) 123.38 (2)
Ask (Size) 123.46 (2)
Prev. Close 119.23
Today's Range 119.23 - 119.23
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Novo Nordisk missed Q2 earnings estimates and announced plans to resubmit Wegovy STEP HFpEF trial results for FDA review in early 2025. Despite strong trial data, the FDA requested more extensive... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+16.77%
+16.77%
1 Month
-16.66%
-16.66%
3 Month
-5.89%
-5.89%
6 Month
+0.48%
+0.48%
1 Year
+26.06%
+26.06%

More News

Read More
Stocks To Watch Today: AXON, LYFT, And Novo Nordisk
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today
Via The Motley Fool
NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
Via InvestorPlace
Novo Nordisk Unusual Options Activity For August 06
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
Via Benzinga
What's Going On With Eli Lilly And Company Shares Wednesday?
Via Benzinga
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Ozempic-Maker Novo Nordisk Reveals Patients Stay On Wegovy Weight-Loss Drug For 6 Months Due To Low Availability
Via Benzinga
Novo Nordisk Slumps On Second-Quarter Miss, Light Ozempic, Wegovy Sales
Via Investor's Business Daily
NVO Stock Earnings: Novo Nordisk Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
Via Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
Via FinancialNewsMedia
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Via Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
Via Benzinga
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
Via The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Via Benzinga
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.